Vanda Pharmaceuticals Inc. revenue
Vanda Pharmaceuticals Inc.'s revenue was $216m in fiscal 2025, up 8.7% on the year before. Since fiscal 2009 ($4.5m) it has grown at a compound 27.3% a year. Over the last twelve months it was $229m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 36 | 31 | 33 | 34 | 50 | 110 | 146 | 165 | 193 | 227 | 248 | 269 | 254 | 193 | 199 | 216 | 229 |
| Growth on the year before | — | +685.2% | −12.4% | +4.7% | +3.5% | +48.0% | +119.2% | +32.8% | +13.1% | +17.0% | +17.6% | +9.2% | +8.3% | −5.3% | −24.3% | +3.2% | +8.7% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Fanapt | $117M | 54.3% | ▲ 24.4% |
| Hetlioz | $71.4M | 33.1% | ▼ 6.8% |
| PONVORY | $27.4M | 12.7% | ▼ 1.5% |
From Vanda Pharmaceuticals Inc.'s 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. | $229m | 8.1% | 2.7% |
| Aurora Cannabis Inc | $232m | 11.7% | — |
| Harrow, Inc. | $276m | 21.1% | 39.0% |
| Organigram Global Inc. | $185m | 57.8% | — |
| Biote Corp. | $184m | -7.8% | 0.5% |
| Kamada LTD | $180m | 12.1% | — |
Compare with peers
- Aurora Cannabis Inc revenue
- Harrow, Inc. revenue
- Organigram Global Inc. revenue
- Biote Corp. revenue
- Kamada LTD revenue
Head to head: ACB vs VNDAHROW vs VNDAOGI vs VNDA
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies